Related Experiment Video
Updated: Nov 29, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Surgery for limited stage small cell lung cancer
Anna K Gergen1, Christopher D Scott1, John D Mitchell1
1Division of Cardiothoracic Surgery, University of Colorado, Aurora, CO, USA.
Journal of Thoracic Disease
|November 19, 2020
Summary
Surgery is increasingly considered for early-stage small cell lung cancer (SCLC), offering excellent survival outcomes. This review examines current evidence supporting surgical resection for limited-stage SCLC.
Area of Science:
- Oncology
- Thoracic Surgery
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with a historically poor prognosis.
- Chemotherapy and radiotherapy are traditional mainstays of SCLC treatment.
- Recent evidence suggests potential benefits of surgical intervention for early-stage disease.
Purpose of the Study:
- To review the existing evidence on the role and efficacy of surgical resection for limited-stage small cell lung cancer.
- To evaluate the historical and current data supporting surgical options in SCLC management.
Main Methods:
- Review of retrospective and observational studies.
- Analysis of survival data for early-stage SCLC patients treated with surgery.
- Synthesis of past and present evidence regarding surgical management.
Main Results:
- Multiple studies indicate excellent survival rates for early-stage SCLC patients undergoing surgical resection.
- Surgical resection is emerging as a viable option for select patients with limited-stage SCLC.
Conclusions:
- Surgical resection demonstrates promising survival benefits for early-stage small cell lung cancer.
- The role of surgery in the multidisciplinary treatment of limited-stage SCLC warrants further investigation and consideration.
